Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment:Several Unanswered Questions  

作　　者：Le Li Zhen-Zhen Li Li-Xin Pan Jia-Yong Su Shan Huang Liang Ma Jian-Hong Zhong 

机构地区：[1]Hepatobiliary Surgery Department,Guangxi Medical University Cancer Hospital,Nanning,Guangxi,China [2]Guangxi Academy of Medical Sciences,Emergency Department,The People’s Hospital of Guangxi Zhuang Autonomous Region,Nanning,Guangxi,China [3]Pathology Department,Guangxi Medical University Cancer Hospital,Nanning,Guangxi,China [4]Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor(Guangxi Medical University),Ministry of Education,Nanning,Guangxi,China [5]Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor,Nanning,Guangxi,China

出　　处：《Journal of Clinical and Translational Hepatology》2024年第5期525-533,共9页临床与转化肝病杂志（英文版）

基　　金：supported by the Specific Research Project of Guangxi for Research Bases and Talents(GuiKe AD22035057);Guangxi Key Research and Development Plan Project(GuiKe AB24010082);Guangxi TCM appropriate technology development and promotion project(GZSY23-66);the Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor(Guangxi Medical University),Ministry of Education(GKE-ZZ202217 and GKE-ZZ202311).

摘　　要：Most patients with hepatocellular carcinoma(HCC)have a poor prognosis.Hepatectomy and local ablation are the main curative treatments for HCC.Nevertheless,the recurrence rate after hepatectomy or ablation is up to 70%,which seriously affects patient prognosis.Several adjuvant therapies have been explored to reduce postoperative recurrence.However,although a variety of adjuvant therapies have been shown to reduce the recurrence rate and improve overall survival,a standard consensus of national HCC guidelines for adjuvant treatment is lacking.Therefore,there are significant differences in the recommendations for adjuvant therapy for HCC between the Eastern and Western guidelines.A variety of adjuvant treatment methods,such as antiviral therapy,transarterial chemoembolization or traditional Chinese medicine,are recommended by the Chinese HCC guidelines.However,Western guidelines make few recommendations other than antiviral therapy.Adjuvant immune checkpoint inhibitors are recommended only in the recently updated American Association for the Study of Liver Diseases guidelines.This review summarized the existing adjuvant therapy options after curative hepatectomy or ablation and discusses several important dilemmas of adjuvant treatments.

关 键 词：Hepatocellular carcinoma Adjuvant therapy Curative hepatectomy RECURRENCE Overall survival Immune checkpoint inhibitor 

分 类 号：R735.7[医药卫生—肿瘤]